Imeglimin enhances α-to-β reprograming mediated by PDX1 in β-cell ablated islets

Area of Science:

• Endocrinology
• Regenerative Medicine
• Cell Biology

Background:

• Diabetes mellitus is caused by insufficient insulin secretion from pancreatic beta cells.
• Generating functional beta cells for diabetes therapy remains a significant challenge.
• Pancreatic alpha cells can be reprogrammed into insulin-producing cells using transcription factors like PDX1.

Purpose of the Study:

• To investigate the effect of the antidiabetic agent imeglimin on alpha-to-beta cell reprogramming.
• To assess imeglimin's potential to enhance the generation of functional surrogate beta cells.

Main Methods:

• Utilized a transgenic mouse model with PDX1 expression in alpha cells.
• Administered imeglimin to assess its impact on alpha-to-beta cell reprogramming efficiency.
• Induced beta-cell ablation using alloxan to evaluate imeglimin's effect under diabetic conditions.

Main Results:

• Exogenous PDX1 expression reprogrammed ~16.5% of alpha cells into insulin-producing cells.
• Imeglimin significantly enhanced reprogramming efficiency by 27.8% (2 weeks) and 48.7% (4 weeks).
• Imeglimin further boosted reprogramming to 58.4% after beta-cell ablation and reduced non-functional reprogrammed cells.

Conclusions:

• Imeglimin treatment effectively promotes alpha-to-beta cell reprogramming in the presence of PDX1.
• Imeglimin may help maintain the function of surrogate beta cells under diabetic conditions.
• This study suggests imeglimin's potential role in developing cell therapies for diabetes.